Peptide Purity: What HPLC Percentages and COAs Actually Mean

Peptide purity language is borrowed from analytical chemistry, where each number has a narrow and specific meaning. A figure such as "98.6%" on a certificate of analysis (COA) is not a general quality score. It is the output of one instrument, run under one method, reporting one kind of comparison. Understanding what that comparison is — and what it structurally cannot see — is the difference between reading a document and trusting a headline. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or the use of any substance.

What a Purity Percentage Actually Describes

In most peptide documentation, the purity number is a relative area percentage: the area of the main chromatographic peak divided by the total area of all detected peaks, expressed as a percent. That definition carries three built-in limits. It only counts what the detector responds to, only what the column separates, and only what elutes during the run.

A formal, metrologically rigorous purity value is a different calculation. Researchers developing an SI-traceable purity assignment for synthetic oxytocin used a mass balance approach in which the peptide content was determined by subtracting all measured non-peptide components — including related structural impurities, water, counter-ions and residual solvents — from the total mass (https://pubmed.ncbi.nlm.nih.gov/34656934/). The study framed purity as a mass fraction of the material in the vial rather than a peak ratio on a trace, which is why a chromatographic percentage and a mass-balance percentage can describe the same material and still disagree.

That distinction matters in ordinary terms. A lyophilised peptide powder contains the peptide, plus whatever counter-ion the synthesis left behind, plus adsorbed water, plus buffer or excipient residues. None of those appear as impurity peaks in a typical chromatogram, because most of them are invisible to the detector used. A material can be 99% pure by peak area and still be substantially less than 99% peptide by weight, without any contradiction between the two figures.

Reversed-Phase HPLC in Plain Language

Reversed-phase high performance liquid chromatography (RP-HPLC) is the workhorse behind nearly every peptide purity figure. A protocol chapter on reversed-phase HPLC of proteins described the technique as a separation in which molecules partition between a hydrophobic stationary phase and a flowing mobile phase, with an increasing organic solvent gradient progressively releasing the bound species (https://pubmed.ncbi.nlm.nih.gov/20814934/). Species that are more hydrophobic hold onto the column longer and emerge later; the detector records each as a peak.

Two practical consequences follow. First, separation is by hydrophobicity, so two different molecules with similar hydrophobicity can co-elute and be counted as one peak. Second, the reported percentage depends on the method — column chemistry, gradient slope, run length and detection wavelength all shape which impurities are resolved and which are hidden. This is why a serious COA reports the method conditions alongside the number, and why a purity figure with no stated method is an assertion rather than a measurement.

What the detector sees

Most peptide HPLC uses ultraviolet absorbance, typically at wavelengths where the peptide bond or aromatic residues absorb. Substances that do not absorb at that wavelength — many salts, some solvents — contribute nothing to the total peak area and therefore cannot reduce the percentage. The mass balance work on synthetic oxytocin addressed precisely this gap by measuring those components separately rather than inferring them from a chromatogram (https://pubmed.ncbi.nlm.nih.gov/34656934/).

What Mass Spectrometry Adds

HPLC answers "how many things are there and in what proportion." Mass spectrometry answers "what is each thing." A methods chapter on mass spectrometric analysis of proteins described the approach as ionising the sample and measuring mass-to-charge ratios to characterise and identify the species present (https://pubmed.ncbi.nlm.nih.gov/28470619/). For a peptide, this is the test of identity: does the measured mass correspond to the intended sequence's theoretical mass?

Coupling the two techniques is what allows impurities to be named rather than merely counted. Researchers characterising structurally related impurities in Cbf-14, a novel antimicrobial peptide, used HPLC-QTOF-MS/MS to separate the impurity peaks and then assign structures to them from their fragmentation patterns (https://pubmed.ncbi.nlm.nih.gov/35840670/). The study illustrated a general point about documentation: a chromatogram shows that side peaks exist, while tandem mass spectrometry is what identifies them as specific sequence-related species.

Peptide mapping logic also appears outside purity testing. Researchers identifying fibronectin-binding peptides within gelatin worked from a complex peptide mixture and used analytical characterisation to pick out and describe specific sequences (https://pubmed.ncbi.nlm.nih.gov/36145902/), and a protocol for digesting peptidoglycan and analysing the soluble fragments described chromatographic separation as the step that turns a mixture into resolvable, individually analysable components (https://pubmed.ncbi.nlm.nih.gov/28932761/). Both reflect the same principle a COA depends on: separation first, identification second.

Where Impurities Come From: What Studies Report

Impurity profiles are largely a function of how a peptide was made. Two broad routes appear in the literature.

Solid-phase chemical synthesis

Stepwise chemical synthesis builds a sequence one residue at a time on a solid support. A study describing Amino-Li-Resin, a fiber polyacrylamide resin, characterised the resin as a support material for solid-phase peptide synthesis (https://pubmed.ncbi.nlm.nih.gov/35267752/). Because each cycle is a chemical reaction with less than perfect yield, the crude product of any stepwise synthesis contains sequence-related species alongside the target — the category that the Cbf-14 impurity work described as "structurally related" and resolved by HPLC-QTOF-MS/MS (https://pubmed.ncbi.nlm.nih.gov/35840670/).

Folding and disulfide complexity

Peptides with multiple cysteines add a second problem: the same atoms can be connected in more than one arrangement. Researchers reporting the total chemical synthesis of aggregation-prone, disulfide-rich starfish peptides described the target molecules as both aggregation-prone and disulfide-rich, which are the two properties that make synthesis and purification difficult (https://pubmed.ncbi.nlm.nih.gov/38609334/). A misfolded disulfide isomer has the identical mass as the correct molecule, so mass spectrometry alone cannot distinguish them — the separation step and orthogonal structural methods carry that burden.

Recombinant and chemically modified peptides

Not all peptides are made synthetically. Researchers reported a biosynthesis route for enfuvirtide using a thermostable chaperone-based fusion system (https://pubmed.ncbi.nlm.nih.gov/35646620/), an approach that shifts the impurity conversation toward host-derived components and fusion-processing products rather than truncated synthesis chains. Chemical modification adds heterogeneity of another kind: a study describing PEGylated leuprolide reported conjugates with improved pharmacokinetic properties relative to the parent peptide (https://pubmed.ncbi.nlm.nih.gov/31926774/), and polymer conjugation generally produces a distribution of species rather than a single defined mass, which complicates what "one peak" means.

Orthogonal Methods and Their Limits

Analytical practice in biologics leans on orthogonal testing — measuring the same attribute by techniques that fail in different ways. A study measuring adenovirus-based vector heterogeneity framed heterogeneity itself as the quantity of interest and applied analytical characterisation to describe it (https://pubmed.ncbi.nlm.nih.gov/36563855/), rather than reducing a complex product to a single number. A review of electrophoretic characterisation of LNP- and AAV-encapsulated nucleic acids was explicit about the trade-off, discussing the strengths and weaknesses of those electrophoretic approaches side by side (https://pubmed.ncbi.nlm.nih.gov/37625008/). The transferable lesson is that no single assay is a complete description of a preparation.

Reading a Certificate of Analysis as a Document

A COA is a report of tests performed on a sample. It is not a property of the container in a reader's hand, and it is not an independent verification. Read as a document, a COA can be examined for internal consistency and completeness:

• Does it name the method? Column, gradient, run time and detection wavelength determine what the percentage could have seen, per the separation principles described for RP-HPLC (https://pubmed.ncbi.nlm.nih.gov/20814934/).
• Does it define the purity basis? Relative peak area and mass-fraction peptide content are different quantities, as the oxytocin mass-balance study made explicit (https://pubmed.ncbi.nlm.nih.gov/34656934/).
• Is identity shown separately from purity? Mass measurement establishes what the molecule is; a chromatogram establishes how much of the signal it represents (https://pubmed.ncbi.nlm.nih.gov/28470619/).
• Are impurities named or only counted? Structural assignment of related impurities required tandem mass spectrometry in the Cbf-14 work (https://pubmed.ncbi.nlm.nih.gov/35840670/).
• Do the identifiers match? Lot number, sequence, molecular formula, test date and the laboratory that performed the testing should agree across every page of the document.
• What is absent? Water content, counter-ion content, residual solvents, endotoxin and sterility are separate determinations and are not implied by a purity percentage.

PeptideU's COA Scanner operates at this level: it reads the structure and internal consistency of an uploaded document. It does not test material, cannot confirm that a document corresponds to any physical sample, and produces no verdict about quality or safety.

Common Misreadings

1. Treating purity as potency. Purity describes composition; none of the cited analytical methods measured biological activity, including the mass-balance assignment of synthetic oxytocin (https://pubmed.ncbi.nlm.nih.gov/34656934/).
2. Treating one peak as one molecule. Disulfide-rich sequences can fold into isomers with identical mass, a difficulty reflected in the synthesis of aggregation-prone disulfide-rich starfish peptides (https://pubmed.ncbi.nlm.nih.gov/38609334/).
3. Expecting one assay to be complete. Heterogeneity measurement in adenovirus-based vectors was approached as a multi-attribute characterisation problem (https://pubmed.ncbi.nlm.nih.gov/36563855/), and electrophoretic methods for encapsulated nucleic acids were reviewed with their weaknesses stated alongside their strengths (https://pubmed.ncbi.nlm.nih.gov/37625008/).
4. Ignoring the production route. Chemical synthesis on resin supports (https://pubmed.ncbi.nlm.nih.gov/35267752/) and recombinant chaperone-fusion biosynthesis, as researchers reported for enfuvirtide (https://pubmed.ncbi.nlm.nih.gov/35646620/), generate different impurity families that different tests are designed to detect.

Many research-grade peptides are labelled for research use only and are not approved medicines; analytical documentation describes a sample, not a regulatory status. Nothing here is guidance about obtaining, preparing or administering any compound.

References

• Reversed-phase High Performance Liquid Chromatography of proteins (Current Protocols in Protein Science, 2010)
• Mass Spectrometric Analysis of Proteins (Methods in Molecular Biology, 2017)
• Mass balance method for SI-traceable purity assignment of synthetic oxytocin (Journal of Pharmaceutical and Biomedical Analysis, 2022)
• Characterization of structurally related peptide impurities using HPLC-QTOF-MS/MS: application to Cbf-14, a novel antimicrobial peptide (Analytical and Bioanalytical Chemistry, 2022)
• Amino-Li-Resin-A Fiber Polyacrylamide Resin for Solid-Phase Peptide Synthesis (Polymers, 2022)
• Total Chemical Synthesis of Aggregation-Prone Disulfide-Rich Starfish Peptides (Chemistry - A European Journal, 2024)
• Enfuvirtide biosynthesis in thermostable chaperone-based fusion (Biotechnology Reports, 2022)
• PEGylated leuprolide with improved pharmacokinetic properties (Bioorganic & Medicinal Chemistry, 2020)
• Measurement of Adenovirus-Based Vector Heterogeneity (Journal of Pharmaceutical Sciences, 2023)
• Electrophoretic characterization of LNP/AAV-encapsulated nucleic acids: Strengths and weaknesses (Electrophoresis, 2023)
• Identification and Characterization of Fibronectin-Binding Peptides in Gelatin (Polymers, 2022)
• Digestion of Peptidoglycan and Analysis of Soluble Fragments (Bio-protocol, 2017)